Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model

Impaired type I interferons (IFNs) production or signaling have been associated with severe COVID-19, further promoting the evaluation of recombinant type I IFNs as therapeutics against SARS-CoV-2 infection. In the Syrian hamster model, we show that intranasal administration of IFN-α starting one da...

Descripción completa

Detalles Bibliográficos
Autores principales: Bessière, Pierre, Wasniewski, Marine, Picard-Meyer, Evelyne, Servat, Alexandre, Figueroa, Thomas, Foret-Lucas, Charlotte, Coggon, Amelia, Lesellier, Sandrine, Boué, Frank, Cebron, Nathan, Gausserès, Blandine, Trumel, Catherine, Foucras, Gilles, Salguero, Francisco J., Monchatre-Leroy, Elodie, Volmer, Romain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376007/
https://www.ncbi.nlm.nih.gov/pubmed/34370799
http://dx.doi.org/10.1371/journal.ppat.1009427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376007/
https://www.ncbi.nlm.nih.gov/pubmed/34370799
http://dx.doi.org/10.1371/journal.ppat.1009427

Ejemplares similares